Breaking News

Shire, Santaris Extend Strategic Alliance

August 23, 2013

Will continue antisense development

Santaris Pharma A/S and Shire have extended their existing partnership for the development of therapies for rare genetic diseases. Shire will have the right to select additional targets for drug discovery and development. Santaris will receive an upfront payment and is eligible for research support, preclinical, clinical and sales milestones, as well as royalties on any products resulting from the collaboration.
 
Henrik Stage, president and chief executive officer at Santaris Pharma, said, "Our collaboration with Shire is very important to us so we are very pleased with the decision to extend the agreement and allow for more drug discovery and development programs. We believe the LNA drug platform offers a unique opportunity to develop drugs against the rapidly expanding number of disease targets in the rare genetic disorder space."
 
Albert Seymour, vice president of discovery research, Shire, said, "We are delighted with our partnership with Santaris, whose expertise and capabilities in LNA antisense therapy complement Shire's drug discovery and development strengths. Our hope is that the partnership will eventually translate into novel drugs that will help patients suffering from debilitating rare diseases lead better lives." 

Related Contract Manufacturing:

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry